S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
Study Details
Study Description
Brief Summary
This randomized phase II trial compares how well two different doses of carfilzomib work when given with dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement or has not responded to treatment. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib together with dexamethasone may kill more cancer cells. It is not yet known whether a higher or lower dose of carfilzomib works better when given with dexamethasone.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
PRIMARY OBJECTIVES:
- To evaluate and compare progression free survival (PFS) of two different doses of carfilzomib with dexamethasone in multiple myeloma (MM) patients with relapsed and/or refractory disease.
SECONDARY OBJECTIVES:
-
To evaluate and compare response rates (RR) for each arm. II. To evaluate response rates (RR) for patients that relapse on low dose carfilzomib and subsequently cross-over to high dose carfilzomib.
-
To evaluate the safety of this combination for this patient population. IV. To evaluate overall survival (OS).
TERTIARY OBJECTIVES:
-
To explore the molecular variability in MM cells obtained from extramedullary bone marrow relapse sites.
-
To explore the role of positron emission tomography (PET) scanning in assessing disease burden and as a tool to assess treatment response.
-
To explore changes in left ventricular ejection fraction (LVEF) in patients with relapsed or refractory multiple myeloma treated with low dose carfilzomib or high dose carfilzomib plus dexamethasone.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive dexamethasone intravenously (IV) and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. Patients with progression cross-over to Arm II.
ARM II: Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16.
Note that for the first course of treatment on both arms carfilzomib is given at a reduced rate to assess toxicity.
In both arms, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 3 years from initial registration.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Arm I (dexamethasone, low-dose carfilzomib) Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II. |
Drug: Carfilzomib
Given IV
Other Names:
Drug: Dexamethasone
Given IV
Other Names:
Other: Laboratory Biomarker Analysis
Correlative studies
|
Experimental: Arm II (dexamethasone, high-dose carfilzomib) Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. |
Drug: Carfilzomib
Given IV
Other Names:
Drug: Dexamethasone
Given IV
Other Names:
Other: Laboratory Biomarker Analysis
Correlative studies
|
Outcome Measures
Primary Outcome Measures
- Progression-free Survival [From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 2 years]
Assessed in each arm using the method of Kaplan Meier and compared between arms using the stratified long-rank test. Progression is defined using the International Uniform Response Criteria for Multiple Myeloma as new or increase in size of existing bone lesions or soft tissue plasmacytomas; or development of hypercalcemia attributable solely to MM; or ≥ 25% increase from baseline or lowest response level of either serum M protein, urine M protein, difference in involved & uninvolved serum free light chain level or bone marrow plasma cell percentage.
Secondary Outcome Measures
- Overall Survival [From date of registration to date of death due to any cause, assessed up to 3 years]
Assessed in each arm using the method of Kaplan Meier and compared between arms using the stratified log-rank test.
- Best Overall Response - Partial Response (PR), Very Good Partial Response (VGPR), Unconfirmed PR (uPR), Stable Disease (SD) Progression (PROG) [From date of registration to date of best response while on study treatment]
Per International Uniform Response Criteria for Multiple Myeloma PR- ≥ 50% reduction in size of soft tissue plasmacytomas & plasma cells; ≥ 50% decrease in serum & reduction in urine M protein ≥ 90% or to < 200 mg/24hr or ≥ 50% decrease in difference in uninvolved & involved serum free light chain levels; VGPR- PR + Serum and urine M proteins detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M protein & urine M protein < 100 mg/24 hrs; uPR- 1 objective status of PR, but confirmation studies are not done, or do not meet the requirements necessary to confirm response; SD- does not meet criteria for sCR, CR, VGPR, PR or PROG; PROG- new or increase in size of existing bone lesions or soft tissue plasmacytomas/ development of hypercalcemia attributable solely to MM/ ≥ 25% increase from baseline/ lowest response level of either serum or Urine M protein, difference in involved & uninvolved serum free light chain level or bone marrow plasma cell percentage.
- Progression-free Survival of Crossover Group [From date of crossover to date of subsequent documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years from randomization]
Assessed in the crossover arm using the method of Kaplan Meier. Progression is defined using the International Uniform Response Criteria for Multiple Myeloma as new or increase in size of existing bone lesions or soft tissue plasmacytomas; or development of hypercalcemia attributable solely to MM; or ≥ 25% increase from baseline or lowest response level of either serum M protein, urine M protein, difference in involved & uninvolved serum free light chain level or bone marrow plasma cell percentage.
- Overall Survival Crossover Group [From date of crossover to date of death due to any cause, assessed up to 3 years from randomization]
Assessed in the crossover arm using the method of Kaplan Meier.
Other Outcome Measures
- Gene Expression Profiles [Up to 3 years]
Bone marrow compared to that of an aspirate taken at the site of the EMP. Data will be log-transformed before analysis. Exploratory analyses will examine underlying distributions using boxplots, density plots, scatter plots, etc. For differential expression analysis of the two sample types t-tests will be conducted on genes. False discovery rate will be used to control the average false positive proportions among selected genes. Genes will be ranked by their q-value and pathway analysis conducted upon selected genes to determine biological plausibility and relevance to molecular functionality.
- Incidence of CR by PET, Defined as the Disappearance of All Focal Lesions and the Resolution of EMD [Up to week 45]
Univariate and multivariate logistic regression will be used to determine the impact of biochemical CR on CR by PET. In the multivariate analysis adjustment for standard prognostic factors such as age, albumin, beta-2 microglobulin, serum creatinine, c-reactive protein and lactate dehydrogenase will be included.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
REGISTRATION STEP 1: INITIAL RANDOMIZATION
-
Patients must have a confirmed diagnosis of symptomatic multiple myeloma and must be currently relapsed or refractory; all tests for establishing disease status must be completed within 28 days prior to registration and documented on the Baseline Tumor Assessment Form for Multiple Myeloma
-
Patients must have measurable disease within 28 days prior to registration
-
Patients must have received at least one prior regimen of chemotherapy for symptomatic multiple myeloma; patients may not have more than six (6) previous regimens of therapy for the disease; prior chemotherapy must have been completed at least 21 days prior to registration; for study purposes, a regimen is defined as follows:
-
An anti-myeloma therapy used at the time of initial diagnosis or documented disease progression which is given with the intent to decrease disease burden
-
Any maintenance therapy used after an Induction should be considered part of that Induction regimen
-
Use of any agent or combination of agents more than once during the patient's disease history for separate documented disease progressions will be counted as separate regimens (e.g., if a patient receives lenalidomide/bortezomib at initial diagnosis and achieves response, but then progresses and receives lenalidomide/bortezomib after progression, these count as 2 separate regimens)
-
In cases of allogeneic or autologous stem cell transplant, the entire induction + stem cell mobilization + conditioning + planned maintenance should be considered one regimen
-
Patients may not have received any prior carfilzomib treatment
-
Patients must not be receiving any other concurrent therapy considered to be investigational; patients must not be planning to receive any radiotherapy (except localized radiation for palliative care); patients must not be planning to receive any concurrent chemotherapy, immunotherapy, radiotherapy or other treatment with curative intent
-
Patients must have complete history and physical examination within 28 days prior to registration
-
Patients must have baseline PET scan within 28 days prior to registration; note that images are submitted centrally for review
-
Patients with non-secretory MM or known primary amyloidosis are not eligible
-
Patients must have Zubrod performance status 0-2
-
Patients must not have clinically significant illness including uncontrolled, active infection requiring intravenous antibiotics, New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or >= grade 3 cardiac arrhythmias
-
Patients must have undergone an electrocardiogram (EKG) within 28 days prior to registration
-
Patients must have either echocardiogram (ECHO) with ejection fraction >= 45% within 28 days prior to registration
-
Patients must not have > grade 2 neuropathy and/or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
-
Total bilirubin =< 1.5 x upper limit of normal (ULN)
-
Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =< 3 x ULN
-
Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support within 14 days prior to registration
-
Platelets >= 50,000 cells/mm3 for patients who have bone marrow plasmacytosis < 50% or >= 30,000 cells/mm3 for patients who have bone marrow plasmacytosis of >= 50% within 14 days prior to registration
-
Calculated or measured creatinine clearance >= 30 ml/min within 14 days prior to registration
-
Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:
-
Cluster of differentiation (CD)4 cells >= 500/mm^3
-
Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART
-
No zidovudine or stavudine as part of cART
-
Patients who are HIV+ and do not meet all of these criteria are not eligible for this study
-
Patients with known hepatitis B or hepatitis C infection must have viral load < 800,000 IU/L within 28 days prior to registration
-
Patients must have baseline skeletal survey to document lytic lesions, osteopenia or compression fracture within 28 days prior to registration
-
Patients may have received palliative external beam radiation therapy (XRT) for local disease control with no curative intent. XRT must be completed at least 7 days prior to registration
-
Patients must be offered participation in specimen submission for translational medicine studies and banking; with patient consent, specimens must be submitted
-
Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
-
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years
-
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
-
As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
-
REGISTRATION STEP 2: CROSSOVER
-
Patient must have been eligible for and initially randomized to Arm 1 (low dose carfilzomib), begun cycle 2 of treatment, and progressed prior to completing 12 cycles of protocol therapy
-
At least 14 days and no more than 28 days must have elapsed between the last day of treatment on Arm 1 and registration to Arm 3
-
Patients must have recovered from all non-hematologic toxicities to =< grade 2 and from all hematologic toxicities to =< grade 3 prior to registration
-
Patients must have begun cycle 2 (carfilzomib - 27 mg/m^2) and must not have received any dose reduction for toxicity in the last cycle of treatment, immediately preceding progression
-
Patients must have serum protein electrophoresis (SPEP) and kappa and lambda light chain testing performed within 14 days prior to registration in order to establish baseline measurements
-
Patients must not have ejection fraction decrease > 10% from baseline (as determined by ECHO) or other ejection fraction decrease accompanied by other clinical signs/symptoms of New York Heart Association (NYHA) class III or IV heart failure, measured within 28 days prior to registration; if any question exists regarding individual patient eligibility in this situation, contact the study chair for determination
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Fairbanks Memorial Hospital | Fairbanks | Alaska | United States | 99701 |
2 | University of Arizona Cancer Center-North Campus | Tucson | Arizona | United States | 85719 |
3 | The University of Arizona Medical Center-University Campus | Tucson | Arizona | United States | 85724 |
4 | Kaiser Permanente-Anaheim | Anaheim | California | United States | 92807 |
5 | Kaiser Permanente-Deer Valley Medical Center | Antioch | California | United States | 94531 |
6 | Sutter Auburn Faith Hospital | Auburn | California | United States | 95602 |
7 | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn | California | United States | 95603 |
8 | Kaiser Permanente-Baldwin Park | Baldwin Park | California | United States | 91706 |
9 | Kaiser Permanente-Bellflower | Bellflower | California | United States | 90706 |
10 | Alta Bates Summit Medical Center-Herrick Campus | Berkeley | California | United States | 94704 |
11 | Mills - Peninsula Hospitals | Burlingame | California | United States | 94010 |
12 | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park | California | United States | 95682 |
13 | Eden Hospital Medical Center | Castro Valley | California | United States | 94546 |
14 | John Muir Medical Center-Concord Campus | Concord | California | United States | 94520 |
15 | Sutter Davis Hospital | Davis | California | United States | 95616 |
16 | Kaiser Permanente Hospital | Fontana | California | United States | 92335 |
17 | Kaiser Permanente-Fremont | Fremont | California | United States | 94538 |
18 | Kaiser Permanente | Fresno | California | United States | 93720 |
19 | Kaiser Permanente - Harbor City | Harbor City | California | United States | 90710 |
20 | Kaiser Permanente-Irvine | Irvine | California | United States | 92618 |
21 | Kaiser Permanente Los Angeles Medical Center | Los Angeles | California | United States | 90027 |
22 | Los Angeles County-USC Medical Center | Los Angeles | California | United States | 90033 |
23 | USC / Norris Comprehensive Cancer Center | Los Angeles | California | United States | 90033 |
24 | Kaiser Permanente-Cadillac | Los Angeles | California | United States | 90034 |
25 | Fremont - Rideout Cancer Center | Marysville | California | United States | 95901 |
26 | Memorial Medical Center | Modesto | California | United States | 95355 |
27 | Kaiser Permanente-Modesto | Modesto | California | United States | 95356 |
28 | Palo Alto Medical Foundation-Camino Division | Mountain View | California | United States | 94040 |
29 | Palo Alto Medical Foundation-Gynecologic Oncology | Mountain View | California | United States | 94040 |
30 | USC Norris Oncology/Hematology-Newport Beach | Newport Beach | California | United States | 92663 |
31 | Sutter Cancer Research Consortium | Novato | California | United States | 94945 |
32 | Kaiser Permanente-Oakland | Oakland | California | United States | 94611 |
33 | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange | California | United States | 92868 |
34 | Palo Alto Medical Foundation Health Care | Palo Alto | California | United States | 94301 |
35 | Kaiser Permanente - Panorama City | Panorama City | California | United States | 91402 |
36 | Kaiser Permanente-Redwood City | Redwood City | California | United States | 94063 |
37 | Kaiser Permanente-Richmond | Richmond | California | United States | 94801 |
38 | Kaiser Permanente-Riverside | Riverside | California | United States | 92505 |
39 | Kaiser Permanente-Roseville | Roseville | California | United States | 95661 |
40 | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville | California | United States | 95661 |
41 | Sutter Roseville Medical Center | Roseville | California | United States | 95661 |
42 | Sutter General Hospital | Sacramento | California | United States | 95816 |
43 | University of California Davis Comprehensive Cancer Center | Sacramento | California | United States | 95817 |
44 | Kaiser Permanente-South Sacramento | Sacramento | California | United States | 95823 |
45 | Kaiser Permanente - Sacramento | Sacramento | California | United States | 95825 |
46 | Kaiser Permanente-San Diego Mission | San Diego | California | United States | 92108 |
47 | Kaiser Permanente-San Diego Zion | San Diego | California | United States | 92120 |
48 | California Pacific Medical Center-Pacific Campus | San Francisco | California | United States | 94115 |
49 | Kaiser Permanente-San Francisco | San Francisco | California | United States | 94115 |
50 | Kaiser Permanente-Santa Teresa-San Jose | San Jose | California | United States | 95119 |
51 | Kaiser Permanente San Leandro | San Leandro | California | United States | 94577 |
52 | Kaiser Permanente-San Marcos | San Marcos | California | United States | 92069 |
53 | Kaiser Permanente-San Rafael | San Rafael | California | United States | 94903 |
54 | Kaiser Permanente Medical Center - Santa Clara | Santa Clara | California | United States | 95051 |
55 | Palo Alto Medical Foundation-Santa Cruz | Santa Cruz | California | United States | 95065 |
56 | Kaiser Permanente-Santa Rosa | Santa Rosa | California | United States | 95403 |
57 | Sutter Pacific Medical Foundation | Santa Rosa | California | United States | 95403 |
58 | Kaiser Permanente-South San Francisco | South San Francisco | California | United States | 94080 |
59 | Kaiser Permanente-Stockton | Stockton | California | United States | 95210 |
60 | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale | California | United States | 94086 |
61 | Gene Upshaw Memorial Tahoe Forest Cancer Center | Truckee | California | United States | 96161 |
62 | Sutter Cancer Centers Radiation Oncology Services-Vacaville | Vacaville | California | United States | 95687 |
63 | Kaiser Permanente Medical Center-Vacaville | Vacaville | California | United States | 95688 |
64 | Kaiser Permanente-Vallejo | Vallejo | California | United States | 94589 |
65 | Sutter Solano Medical Center/Cancer Center | Vallejo | California | United States | 94589 |
66 | Kaiser Permanente-Walnut Creek | Walnut Creek | California | United States | 94596 |
67 | John Muir Medical Center-Walnut Creek | Walnut Creek | California | United States | 94598 |
68 | Kaiser Permanente | Woodland Hills | California | United States | 91367 |
69 | Smilow Cancer Hospital-Derby Care Center | Derby | Connecticut | United States | 06418 |
70 | Smilow Cancer Hospital Care Center-Fairfield | Fairfield | Connecticut | United States | 06824 |
71 | Medical Oncology and Hematology Group PC-Guilford | Guilford | Connecticut | United States | 06437 |
72 | Smilow Cancer Hospital Care Center at Saint Francis | Hartford | Connecticut | United States | 06105 |
73 | Yale University | New Haven | Connecticut | United States | 06520 |
74 | Yale-New Haven Hospital North Haven Medical Center | North Haven | Connecticut | United States | 06473 |
75 | Smilow Cancer Hospital-Orange Care Center | Orange | Connecticut | United States | 06477 |
76 | Charlotte Hungerford Hospital Center for Cancer Care | Torrington | Connecticut | United States | 06790 |
77 | Smilow Cancer Hospital Care Center-Trumbull | Trumbull | Connecticut | United States | 06611 |
78 | Smilow Cancer Hospital-Waterbury Care Center | Waterbury | Connecticut | United States | 06708 |
79 | Beebe Medical Center | Lewes | Delaware | United States | 19958 |
80 | Christiana Gynecologic Oncology LLC | Newark | Delaware | United States | 19713 |
81 | Delaware Clinical and Laboratory Physicians PA | Newark | Delaware | United States | 19713 |
82 | Helen F Graham Cancer Center | Newark | Delaware | United States | 19713 |
83 | Medical Oncology Hematology Consultants PA | Newark | Delaware | United States | 19713 |
84 | Regional Hematology and Oncology PA | Newark | Delaware | United States | 19713 |
85 | Christiana Care Health System-Christiana Hospital | Newark | Delaware | United States | 19718 |
86 | Beebe Health Campus | Rehoboth Beach | Delaware | United States | 19971 |
87 | Nanticoke Memorial Hospital | Seaford | Delaware | United States | 19973 |
88 | Christiana Care Health System-Wilmington Hospital | Wilmington | Delaware | United States | 19801 |
89 | MedStar Georgetown University Hospital | Washington | District of Columbia | United States | 20007 |
90 | MedStar Washington Hospital Center | Washington | District of Columbia | United States | 20010 |
91 | University of Florida | Gainesville | Florida | United States | 32610 |
92 | Mayo Clinic in Florida | Jacksonville | Florida | United States | 32224-9980 |
93 | Florida Hospital Orlando | Orlando | Florida | United States | 32803 |
94 | Lewis Cancer and Research Pavilion at Saint Joseph's/Candler | Savannah | Georgia | United States | 31405 |
95 | Hawaii Oncology Inc-Pali Momi | 'Aiea | Hawaii | United States | 96701 |
96 | Pali Momi Medical Center | 'Aiea | Hawaii | United States | 96701 |
97 | Hawaii Cancer Care Inc-POB II | Honolulu | Hawaii | United States | 96813 |
98 | Queen's Medical Center | Honolulu | Hawaii | United States | 96813 |
99 | Straub Clinic and Hospital | Honolulu | Hawaii | United States | 96813 |
100 | University of Hawaii Cancer Center | Honolulu | Hawaii | United States | 96813 |
101 | Hawaii Cancer Care Inc-Liliha | Honolulu | Hawaii | United States | 96817 |
102 | Hawaii Oncology Inc-Kuakini | Honolulu | Hawaii | United States | 96817 |
103 | Kuakini Medical Center | Honolulu | Hawaii | United States | 96817 |
104 | Kaiser Permanente Moanalua Medical Center | Honolulu | Hawaii | United States | 96819 |
105 | Castle Medical Center | Kailua | Hawaii | United States | 96734 |
106 | Wilcox Memorial Hospital and Kauai Medical Clinic | Lihue | Hawaii | United States | 96766 |
107 | Saint Alphonsus Cancer Care Center-Boise | Boise | Idaho | United States | 83706 |
108 | Kootenai Medical Center | Coeur d'Alene | Idaho | United States | 83814 |
109 | Kootenai Cancer Center | Post Falls | Idaho | United States | 83854 |
110 | Kootenai Cancer Clinic | Sandpoint | Idaho | United States | 83864 |
111 | Rush - Copley Medical Center | Aurora | Illinois | United States | 60504 |
112 | Saint Joseph Medical Center | Bloomington | Illinois | United States | 61701 |
113 | Illinois CancerCare-Bloomington | Bloomington | Illinois | United States | 61704 |
114 | Illinois CancerCare-Canton | Canton | Illinois | United States | 61520 |
115 | Memorial Hospital of Carbondale | Carbondale | Illinois | United States | 62902 |
116 | Illinois CancerCare-Carthage | Carthage | Illinois | United States | 62321 |
117 | Centralia Oncology Clinic | Centralia | Illinois | United States | 62801 |
118 | Carle on Vermilion | Danville | Illinois | United States | 61832 |
119 | Cancer Care Center of Decatur | Decatur | Illinois | United States | 62526 |
120 | Decatur Memorial Hospital | Decatur | Illinois | United States | 62526 |
121 | Carle Physician Group-Effingham | Effingham | Illinois | United States | 62401 |
122 | Crossroads Cancer Center | Effingham | Illinois | United States | 62401 |
123 | Illinois CancerCare-Eureka | Eureka | Illinois | United States | 61530 |
124 | Illinois CancerCare-Galesburg | Galesburg | Illinois | United States | 61401 |
125 | Western Illinois Cancer Treatment Center | Galesburg | Illinois | United States | 61401 |
126 | Hinsdale Hematology Oncology Associates Incorporated | Hinsdale | Illinois | United States | 60521 |
127 | Illinois CancerCare-Kewanee Clinic | Kewanee | Illinois | United States | 61443 |
128 | Illinois CancerCare-Macomb | Macomb | Illinois | United States | 61455 |
129 | Carle Physician Group-Mattoon/Charleston | Mattoon | Illinois | United States | 61938 |
130 | Loyola University Medical Center | Maywood | Illinois | United States | 60153 |
131 | Garneau, Stewart C MD (UIA Investigator) | Moline | Illinois | United States | 61265 |
132 | Porubcin, Michael MD (UIA Investigator) | Moline | Illinois | United States | 61265 |
133 | Spector, David MD (UIA Investigator) | Moline | Illinois | United States | 61265 |
134 | Trinity Medical Center | Moline | Illinois | United States | 61265 |
135 | Illinois CancerCare-Monmouth | Monmouth | Illinois | United States | 61462 |
136 | Good Samaritan Regional Health Center | Mount Vernon | Illinois | United States | 62864 |
137 | Community Cancer Center Foundation | Normal | Illinois | United States | 61761 |
138 | Illinois CancerCare-Ottawa Clinic | Ottawa | Illinois | United States | 61350 |
139 | Radiation Oncology of Northern Illinois | Ottawa | Illinois | United States | 61350 |
140 | Illinois CancerCare-Pekin | Pekin | Illinois | United States | 61554 |
141 | OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center | Pekin | Illinois | United States | 61554 |
142 | Methodist Medical Center of Illinois | Peoria | Illinois | United States | 61603 |
143 | Illinois CancerCare-Peoria | Peoria | Illinois | United States | 61615 |
144 | OSF Saint Francis Radiation Oncology at Peoria Cancer Center | Peoria | Illinois | United States | 61615 |
145 | OSF Saint Francis Medical Center | Peoria | Illinois | United States | 61637 |
146 | Illinois CancerCare-Peru | Peru | Illinois | United States | 61354 |
147 | Valley Radiation Oncology | Peru | Illinois | United States | 61354 |
148 | Illinois CancerCare-Princeton | Princeton | Illinois | United States | 61356 |
149 | SwedishAmerican Regional Cancer Center/ACT | Rockford | Illinois | United States | 61114 |
150 | Central Illinois Hematology Oncology Center | Springfield | Illinois | United States | 62702 |
151 | Southern Illinois University School of Medicine | Springfield | Illinois | United States | 62702 |
152 | Springfield Clinic | Springfield | Illinois | United States | 62702 |
153 | Memorial Medical Center | Springfield | Illinois | United States | 62781 |
154 | Cancer Care Specialists of Illinois-Swansea | Swansea | Illinois | United States | 62226 |
155 | Carle Cancer Center | Urbana | Illinois | United States | 61801 |
156 | The Carle Foundation Hospital | Urbana | Illinois | United States | 61801 |
157 | Rush-Copley Healthcare Center | Yorkville | Illinois | United States | 60560 |
158 | Franciscan Saint Anthony Health-Michigan City | Michigan City | Indiana | United States | 46360 |
159 | Woodland Cancer Care Center | Michigan City | Indiana | United States | 46360 |
160 | Reid Health | Richmond | Indiana | United States | 47374 |
161 | Mary Greeley Medical Center | Ames | Iowa | United States | 50010 |
162 | McFarland Clinic PC-William R Bliss Cancer Center | Ames | Iowa | United States | 50010 |
163 | Constantinou, Costas L MD (UIA Investigator) | Bettendorf | Iowa | United States | 52722 |
164 | Hematology Oncology Associates-Quad Cities | Bettendorf | Iowa | United States | 52722 |
165 | McFarland Clinic PC-Boone | Boone | Iowa | United States | 50036 |
166 | Medical Oncology and Hematology Associates-West Des Moines | Clive | Iowa | United States | 50325 |
167 | Mercy Cancer Center-West Lakes | Clive | Iowa | United States | 50325 |
168 | Genesis Medical Center - East Campus | Davenport | Iowa | United States | 52803 |
169 | Iowa Methodist Medical Center | Des Moines | Iowa | United States | 50309 |
170 | Iowa-Wide Oncology Research Coalition NCORP | Des Moines | Iowa | United States | 50309 |
171 | Medical Oncology and Hematology Associates-Des Moines | Des Moines | Iowa | United States | 50309 |
172 | Medical Oncology and Hematology Associates-Laurel | Des Moines | Iowa | United States | 50314 |
173 | Mercy Medical Center - Des Moines | Des Moines | Iowa | United States | 50314 |
174 | Iowa Lutheran Hospital | Des Moines | Iowa | United States | 50316 |
175 | McFarland Clinic PC-Trinity Cancer Center | Fort Dodge | Iowa | United States | 50501 |
176 | McFarland Clinic PC-Jefferson | Jefferson | Iowa | United States | 50129 |
177 | McFarland Clinic PC-Marshalltown | Marshalltown | Iowa | United States | 50158 |
178 | Siouxland Regional Cancer Center | Sioux City | Iowa | United States | 51101 |
179 | Mercy Medical Center-Sioux City | Sioux City | Iowa | United States | 51104 |
180 | Saint Luke's Regional Medical Center | Sioux City | Iowa | United States | 51104 |
181 | Methodist West Hospital | West Des Moines | Iowa | United States | 50266-7700 |
182 | Mercy Medical Center-West Lakes | West Des Moines | Iowa | United States | 50266 |
183 | Cancer Center of Kansas - Chanute | Chanute | Kansas | United States | 66720 |
184 | Cancer Center of Kansas - Dodge City | Dodge City | Kansas | United States | 67801 |
185 | Cancer Center of Kansas - El Dorado | El Dorado | Kansas | United States | 67042 |
186 | Cancer Center of Kansas - Fort Scott | Fort Scott | Kansas | United States | 66701 |
187 | Cancer Center of Kansas-Independence | Independence | Kansas | United States | 67301 |
188 | Cancer Center of Kansas-Kingman | Kingman | Kansas | United States | 67068 |
189 | Lawrence Memorial Hospital | Lawrence | Kansas | United States | 66044 |
190 | Cancer Center of Kansas-Liberal | Liberal | Kansas | United States | 67905 |
191 | Cancer Center of Kansas-Manhattan | Manhattan | Kansas | United States | 66502 |
192 | Cancer Center of Kansas - McPherson | McPherson | Kansas | United States | 67460 |
193 | Cancer Center of Kansas - Newton | Newton | Kansas | United States | 67114 |
194 | Cancer Center of Kansas - Parsons | Parsons | Kansas | United States | 67357 |
195 | Cancer Center of Kansas - Pratt | Pratt | Kansas | United States | 67124 |
196 | Cancer Center of Kansas - Salina | Salina | Kansas | United States | 67401 |
197 | Cancer Center of Kansas - Wellington | Wellington | Kansas | United States | 67152 |
198 | Associates In Womens Health | Wichita | Kansas | United States | 67208 |
199 | Cancer Center of Kansas-Wichita Medical Arts Tower | Wichita | Kansas | United States | 67208 |
200 | Cancer Center of Kansas - Wichita | Wichita | Kansas | United States | 67214 |
201 | Via Christi Regional Medical Center | Wichita | Kansas | United States | 67214 |
202 | Wichita NCI Community Oncology Research Program | Wichita | Kansas | United States | 67214 |
203 | Cancer Center of Kansas - Winfield | Winfield | Kansas | United States | 67156 |
204 | Oncology Hematology Care Inc-Crestview | Crestview Hills | Kentucky | United States | 41017 |
205 | LSU Health Baton Rouge-North Clinic | Baton Rouge | Louisiana | United States | 70805 |
206 | Hematology/Oncology Clinic LLP | Baton Rouge | Louisiana | United States | 70809 |
207 | Louisiana Hematology Oncology Associates LLC | Baton Rouge | Louisiana | United States | 70809 |
208 | Mary Bird Perkins Cancer Center | Baton Rouge | Louisiana | United States | 70809 |
209 | Medical Oncology LLC | Baton Rouge | Louisiana | United States | 70809 |
210 | Mary Bird Cancer Center/Saint Tammany Parish | Covington | Louisiana | United States | 70433 |
211 | Mary Bird Perkins Cancer Center/Terrebonne General Medical Center | Houma | Louisiana | United States | 70360 |
212 | Tulane University Health Sciences Center | New Orleans | Louisiana | United States | 70112 |
213 | Harold Alfond Center for Cancer Care | Augusta | Maine | United States | 04330 |
214 | Eastern Maine Medical Center | Bangor | Maine | United States | 04401 |
215 | Central Maine Medical Center | Lewiston | Maine | United States | 04240 |
216 | Penobscot Bay Medical Center | Rockport | Maine | United States | 04856 |
217 | Peninsula Regional Medical Center | Salisbury | Maryland | United States | 21801 |
218 | Beverly Hospital | Beverly | Massachusetts | United States | 01915 |
219 | Boston Medical Center | Boston | Massachusetts | United States | 02118 |
220 | Lahey Hospital and Medical Center | Burlington | Massachusetts | United States | 01805 |
221 | Addison Gilbert Hospital | Gloucester | Massachusetts | United States | 01930 |
222 | Bixby Medical Center | Adrian | Michigan | United States | 49221 |
223 | Hickman Cancer Center | Adrian | Michigan | United States | 49221 |
224 | Saint Joseph Mercy Hospital | Ann Arbor | Michigan | United States | 48106-0995 |
225 | Michigan Cancer Research Consortium NCORP | Ann Arbor | Michigan | United States | 48106 |
226 | Beaumont Hospital-Dearborn | Dearborn | Michigan | United States | 48124 |
227 | Wayne State University/Karmanos Cancer Institute | Detroit | Michigan | United States | 48201 |
228 | Henry Ford Hospital | Detroit | Michigan | United States | 48202 |
229 | Saint John Hospital and Medical Center | Detroit | Michigan | United States | 48236 |
230 | Green Bay Oncology - Escanaba | Escanaba | Michigan | United States | 49829 |
231 | Weisberg Cancer Treatment Center | Farmington Hills | Michigan | United States | 48334 |
232 | Hurley Medical Center | Flint | Michigan | United States | 48502 |
233 | Genesys Hurley Cancer Institute | Flint | Michigan | United States | 48503 |
234 | Green Bay Oncology - Iron Mountain | Iron Mountain | Michigan | United States | 49801 |
235 | Allegiance Health | Jackson | Michigan | United States | 49201 |
236 | Borgess Medical Center | Kalamazoo | Michigan | United States | 49001 |
237 | Bronson Methodist Hospital | Kalamazoo | Michigan | United States | 49007 |
238 | West Michigan Cancer Center | Kalamazoo | Michigan | United States | 49007 |
239 | Sparrow Hospital | Lansing | Michigan | United States | 48912 |
240 | Saint Mary Mercy Hospital | Livonia | Michigan | United States | 48154 |
241 | Mercy Memorial Hospital | Monroe | Michigan | United States | 48162 |
242 | Toledo Clinic Cancer Centers-Monroe | Monroe | Michigan | United States | 48162 |
243 | Saint Joseph Mercy Oakland | Pontiac | Michigan | United States | 48341 |
244 | Lake Huron Medical Center | Port Huron | Michigan | United States | 48060 |
245 | Saint Mary's of Michigan | Saginaw | Michigan | United States | 48601 |
246 | Providence Hospital-Southfield Cancer Center | Southfield | Michigan | United States | 48075 |
247 | Saint John Macomb-Oakland Hospital | Warren | Michigan | United States | 48093 |
248 | Sanford Clinic North-Bemidgi | Bemidji | Minnesota | United States | 56601 |
249 | Fairview Ridges Hospital | Burnsville | Minnesota | United States | 55337 |
250 | Mercy Hospital | Coon Rapids | Minnesota | United States | 55433 |
251 | Fairview-Southdale Hospital | Edina | Minnesota | United States | 55435 |
252 | Unity Hospital | Fridley | Minnesota | United States | 55432 |
253 | Hutchinson Area Health Care | Hutchinson | Minnesota | United States | 55350 |
254 | Minnesota Oncology Hematology PA-Maplewood | Maplewood | Minnesota | United States | 55109 |
255 | Saint John's Hospital - Healtheast | Maplewood | Minnesota | United States | 55109 |
256 | Abbott-Northwestern Hospital | Minneapolis | Minnesota | United States | 55407 |
257 | Hennepin County Medical Center | Minneapolis | Minnesota | United States | 55415 |
258 | Health Partners Inc | Minneapolis | Minnesota | United States | 55454 |
259 | New Ulm Medical Center | New Ulm | Minnesota | United States | 56073 |
260 | North Memorial Medical Health Center | Robbinsdale | Minnesota | United States | 55422 |
261 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
262 | Metro Minnesota Community Oncology Research Consortium | Saint Louis Park | Minnesota | United States | 55416 |
263 | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Minnesota | United States | 55416 |
264 | Regions Hospital | Saint Paul | Minnesota | United States | 55101 |
265 | United Hospital | Saint Paul | Minnesota | United States | 55102 |
266 | Saint Francis Regional Medical Center | Shakopee | Minnesota | United States | 55379 |
267 | Lakeview Hospital | Stillwater | Minnesota | United States | 55082 |
268 | Ridgeview Medical Center | Waconia | Minnesota | United States | 55387 |
269 | Rice Memorial Hospital | Willmar | Minnesota | United States | 56201 |
270 | Minnesota Oncology Hematology PA-Woodbury | Woodbury | Minnesota | United States | 55125 |
271 | University of Mississippi Medical Center | Jackson | Mississippi | United States | 39216 |
272 | Central Care Cancer Center-Carrie J Babb Cancer Center | Bolivar | Missouri | United States | 65613 |
273 | Parkland Health Center-Bonne Terre | Bonne Terre | Missouri | United States | 63628 |
274 | CoxHealth Cancer Center | Branson | Missouri | United States | 65616 |
275 | Saint Francis Medical Center | Cape Girardeau | Missouri | United States | 63703 |
276 | Southeast Cancer Center | Cape Girardeau | Missouri | United States | 63703 |
277 | Saint Luke's Hospital | Chesterfield | Missouri | United States | 63017 |
278 | Capital Region Medical Center-Goldschmidt Cancer Center | Jefferson City | Missouri | United States | 65109 |
279 | Freeman Health System | Joplin | Missouri | United States | 64804 |
280 | Delbert Day Cancer Institute at PCRMC | Rolla | Missouri | United States | 65401 |
281 | Saint John's Clinic-Rolla-Cancer and Hematology | Rolla | Missouri | United States | 65401 |
282 | Saint Louis Cancer and Breast Institute-South City | Saint Louis | Missouri | United States | 63109 |
283 | Missouri Baptist Medical Center | Saint Louis | Missouri | United States | 63131 |
284 | Mercy Hospital Saint Louis | Saint Louis | Missouri | United States | 63141 |
285 | Sainte Genevieve County Memorial Hospital | Sainte Genevieve | Missouri | United States | 63670 |
286 | Cancer Research for the Ozarks NCORP | Springfield | Missouri | United States | 65804 |
287 | Mercy Hospital Springfield | Springfield | Missouri | United States | 65804 |
288 | CoxHealth South Hospital | Springfield | Missouri | United States | 65807 |
289 | Missouri Baptist Sullivan Hospital | Sullivan | Missouri | United States | 63080 |
290 | Missouri Baptist Outpatient Center-Sunset Hills | Sunset Hills | Missouri | United States | 63127 |
291 | Billings Clinic Cancer Center | Billings | Montana | United States | 59101 |
292 | Montana Cancer Consortium NCORP | Billings | Montana | United States | 59101 |
293 | Saint Vincent Healthcare | Billings | Montana | United States | 59101 |
294 | Bozeman Deaconess Hospital | Bozeman | Montana | United States | 59715 |
295 | Saint James Community Hospital and Cancer Treatment Center | Butte | Montana | United States | 59701 |
296 | Benefis Healthcare- Sletten Cancer Institute | Great Falls | Montana | United States | 59405 |
297 | Saint Peter's Community Hospital | Helena | Montana | United States | 59601 |
298 | Kalispell Regional Medical Center | Kalispell | Montana | United States | 59901 |
299 | Saint Patrick Hospital - Community Hospital | Missoula | Montana | United States | 59802 |
300 | Community Medical Hospital | Missoula | Montana | United States | 59804 |
301 | Cancer and Blood Specialists-Henderson | Henderson | Nevada | United States | 89052 |
302 | Comprehensive Cancer Centers of Nevada - Henderson | Henderson | Nevada | United States | 89052 |
303 | Las Vegas Cancer Center-Henderson | Henderson | Nevada | United States | 89052 |
304 | 21st Century Oncology - Henderson | Henderson | Nevada | United States | 89074 |
305 | Comprehensive Cancer Centers of Nevada-Southeast Henderson | Henderson | Nevada | United States | 89074 |
306 | University Medical Center of Southern Nevada | Las Vegas | Nevada | United States | 89102 |
307 | Cancer and Blood Specialists-Shadow | Las Vegas | Nevada | United States | 89106 |
308 | Nevada Cancer Research Foundation CCOP | Las Vegas | Nevada | United States | 89106 |
309 | Radiation Oncology Centers of Nevada Central | Las Vegas | Nevada | United States | 89106 |
310 | 21st Century Oncology | Las Vegas | Nevada | United States | 89109 |
311 | HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway | Las Vegas | Nevada | United States | 89109 |
312 | HealthCare Partners Medical Group Oncology/Hematology-San Martin | Las Vegas | Nevada | United States | 89113 |
313 | Radiation Oncology Centers of Nevada Southeast | Las Vegas | Nevada | United States | 89119 |
314 | Cancer Therapy and Integrative Medicine | Las Vegas | Nevada | United States | 89121 |
315 | Cancer and Blood Specialists-Tenaya | Las Vegas | Nevada | United States | 89128 |
316 | Comprehensive Cancer Centers of Nevada - Northwest | Las Vegas | Nevada | United States | 89128 |
317 | HealthCare Partners Medical Group Oncology/Hematology-Tenaya | Las Vegas | Nevada | United States | 89128 |
318 | Comprehensive Cancer Centers of Nevada-Summerlin | Las Vegas | Nevada | United States | 89144 |
319 | Las Vegas Cancer Center-Medical Center | Las Vegas | Nevada | United States | 89148-2405 |
320 | 21st Century Oncology - Fort Apache | Las Vegas | Nevada | United States | 89148 |
321 | Cancer and Blood Specialists-Fort Apache | Las Vegas | Nevada | United States | 89148 |
322 | Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | United States | 89148 |
323 | HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills | Las Vegas | Nevada | United States | 89149 |
324 | Comprehensive Cancer Centers of Nevada - Central Valley | Las Vegas | Nevada | United States | 89169 |
325 | 21st Century Oncology - Vegas Tenaya | Las Vegas | Nevada | United States | 89182 |
326 | Inspira Medical Center Vineland | Vineland | New Jersey | United States | 08360 |
327 | Inspira Medical Center Woodbury | Woodbury | New Jersey | United States | 08096 |
328 | Orange Regional Medical Center | Middletown | New York | United States | 10940 |
329 | Randolph Hospital | Asheboro | North Carolina | United States | 27203 |
330 | Cone Health Cancer Center at Alamance Regional | Burlington | North Carolina | United States | 27215 |
331 | UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | United States | 27599 |
332 | Southeastern Medical Oncology Center-Clinton | Clinton | North Carolina | United States | 28328 |
333 | Southeastern Medical Oncology Center-Goldsboro | Goldsboro | North Carolina | United States | 27534 |
334 | Wayne Memorial Hospital | Goldsboro | North Carolina | United States | 27534 |
335 | Cone Health Cancer Center | Greensboro | North Carolina | United States | 27403 |
336 | Hendersonville Hematology and Oncology at Pardee | Hendersonville | North Carolina | United States | 28791 |
337 | Margaret R Pardee Memorial Hospital | Hendersonville | North Carolina | United States | 28791 |
338 | Southeastern Medical Oncology Center-Jacksonville | Jacksonville | North Carolina | United States | 28546 |
339 | Kinston Medical Specialists PA | Kinston | North Carolina | United States | 28501 |
340 | Cone Heath Cancer Center at Mebane | Mebane | North Carolina | United States | 27302 |
341 | Annie Penn Memorial Hospital | Reidsville | North Carolina | United States | 27320 |
342 | Iredell Memorial Hospital | Statesville | North Carolina | United States | 28677 |
343 | Southeastern Medical Oncology Center-Wilson | Wilson | North Carolina | United States | 27893 |
344 | Wake Forest University Health Sciences | Winston-Salem | North Carolina | United States | 27157 |
345 | Sanford Bismarck Medical Center | Bismarck | North Dakota | United States | 58501 |
346 | Roger Maris Cancer Center | Fargo | North Dakota | United States | 58122 |
347 | Sanford Clinic North-Fargo | Fargo | North Dakota | United States | 58122 |
348 | Sanford Medical Center-Fargo | Fargo | North Dakota | United States | 58122 |
349 | Strecker Cancer Center-Belpre | Belpre | Ohio | United States | 45714 |
350 | Toledo Clinic Cancer Centers-Bowling Green | Bowling Green | Ohio | United States | 43402 |
351 | Aultman Health Foundation | Canton | Ohio | United States | 44710 |
352 | Miami Valley Hospital South | Centerville | Ohio | United States | 45459 |
353 | Adena Regional Medical Center | Chillicothe | Ohio | United States | 45601 |
354 | Oncology Hematology Care Inc-Eden Park | Cincinnati | Ohio | United States | 45202 |
355 | Oncology Hematology Care Inc-Mercy West | Cincinnati | Ohio | United States | 45211 |
356 | Oncology Hematology Care Inc - Anderson | Cincinnati | Ohio | United States | 45230 |
357 | Oncology Hematology Care Inc-Kenwood | Cincinnati | Ohio | United States | 45236 |
358 | Oncology Hematology Care Inc-Blue Ash | Cincinnati | Ohio | United States | 45242 |
359 | Mount Carmel East Hospital | Columbus | Ohio | United States | 43213 |
360 | Columbus Oncology and Hematology Associates Inc | Columbus | Ohio | United States | 43214 |
361 | Riverside Methodist Hospital | Columbus | Ohio | United States | 43214 |
362 | Columbus NCI Community Oncology Research Program | Columbus | Ohio | United States | 43215 |
363 | Grant Medical Center | Columbus | Ohio | United States | 43215 |
364 | The Mark H Zangmeister Center | Columbus | Ohio | United States | 43219 |
365 | Mount Carmel Health Center West | Columbus | Ohio | United States | 43222 |
366 | Doctors Hospital | Columbus | Ohio | United States | 43228 |
367 | Good Samaritan Hospital - Dayton | Dayton | Ohio | United States | 45406 |
368 | Miami Valley Hospital | Dayton | Ohio | United States | 45409 |
369 | Samaritan North Health Center | Dayton | Ohio | United States | 45415 |
370 | Dayton NCI Community Oncology Research Program | Dayton | Ohio | United States | 45420 |
371 | Delaware Health Center-Grady Cancer Center | Delaware | Ohio | United States | 43015 |
372 | Delaware Radiation Oncology | Delaware | Ohio | United States | 43015 |
373 | Grady Memorial Hospital | Delaware | Ohio | United States | 43015 |
374 | Oncology Hematology Care Inc-Healthplex | Fairfield | Ohio | United States | 45014 |
375 | Blanchard Valley Hospital | Findlay | Ohio | United States | 45840 |
376 | Atrium Medical Center-Middletown Regional Hospital | Franklin | Ohio | United States | 45005-1066 |
377 | Wayne Hospital | Greenville | Ohio | United States | 45331 |
378 | Kettering Medical Center | Kettering | Ohio | United States | 45429 |
379 | Fairfield Medical Center | Lancaster | Ohio | United States | 43130 |
380 | Lancaster Radiation Oncology | Lancaster | Ohio | United States | 43130 |
381 | Lima Memorial Hospital | Lima | Ohio | United States | 45804 |
382 | Marietta Memorial Hospital | Marietta | Ohio | United States | 45750 |
383 | OneHealth Marion General Hospital | Marion | Ohio | United States | 43302 |
384 | Toledo Clinic Cancer Centers-Maumee | Maumee | Ohio | United States | 43537 |
385 | Toledo Radiation Oncology at Northwest Ohio Onocolgy Center | Maumee | Ohio | United States | 43537 |
386 | Knox Community Hospital | Mount Vernon | Ohio | United States | 43050 |
387 | Licking Memorial Hospital | Newark | Ohio | United States | 43055 |
388 | Newark Radiation Oncology | Newark | Ohio | United States | 43055 |
389 | Saint Charles Hospital | Oregon | Ohio | United States | 43616 |
390 | Toledo Clinic Cancer Centers-Oregon | Oregon | Ohio | United States | 43616 |
391 | Southern Ohio Medical Center | Portsmouth | Ohio | United States | 45662 |
392 | Springfield Regional Cancer Center | Springfield | Ohio | United States | 45504 |
393 | Springfield Regional Medical Center | Springfield | Ohio | United States | 45505 |
394 | Flower Hospital | Sylvania | Ohio | United States | 43560 |
395 | Mercy Hospital of Tiffin | Tiffin | Ohio | United States | 44883 |
396 | The Toledo Hospital/Toledo Children's Hospital | Toledo | Ohio | United States | 43606 |
397 | Saint Vincent Mercy Medical Center | Toledo | Ohio | United States | 43608 |
398 | University of Toledo | Toledo | Ohio | United States | 43614 |
399 | Toledo Community Hospital Oncology Program CCOP | Toledo | Ohio | United States | 43617 |
400 | Mercy Saint Anne Hospital | Toledo | Ohio | United States | 43623 |
401 | Toledo Clinic Cancer Centers-Toledo | Toledo | Ohio | United States | 43623 |
402 | Upper Valley Medical Center | Troy | Ohio | United States | 45373 |
403 | Fulton County Health Center | Wauseon | Ohio | United States | 43567 |
404 | Saint Ann's Hospital | Westerville | Ohio | United States | 43081 |
405 | Wright-Patterson Medical Center | Wright-Patterson Air Force Base | Ohio | United States | 45433-5529 |
406 | Genesis Healthcare System Cancer Care Center | Zanesville | Ohio | United States | 43701 |
407 | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | United States | 73104 |
408 | Bryn Mawr Hospital | Bryn Mawr | Pennsylvania | United States | 19010 |
409 | Geisinger Medical Center | Danville | Pennsylvania | United States | 17822 |
410 | Geisinger Medical Center-Cancer Center Hazleton | Hazleton | Pennsylvania | United States | 18201 |
411 | Geisinger Medical Oncology-Lewisburg | Lewisburg | Pennsylvania | United States | 17837 |
412 | Lewistown Hospital | Lewistown | Pennsylvania | United States | 17044 |
413 | Riddle Memorial Hospital | Media | Pennsylvania | United States | 19063 |
414 | Paoli Memorial Hospital | Paoli | Pennsylvania | United States | 19301 |
415 | University of Pennsylvania/Abramson Cancer Center | Philadelphia | Pennsylvania | United States | 19104 |
416 | Geisinger Medical Oncology-Pottsville | Pottsville | Pennsylvania | United States | 17901 |
417 | Penn State Health Saint Joseph Medical Center | Reading | Pennsylvania | United States | 19605 |
418 | Grand View Hospital | Sellersville | Pennsylvania | United States | 18960 |
419 | Geisinger Medical Group | State College | Pennsylvania | United States | 16801 |
420 | Reading Hospital | West Reading | Pennsylvania | United States | 19611 |
421 | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre | Pennsylvania | United States | 18711 |
422 | Lankenau Medical Center | Wynnewood | Pennsylvania | United States | 19096 |
423 | Main Line Health NCORP | Wynnewood | Pennsylvania | United States | 19096 |
424 | AnMed Health Cancer Center | Anderson | South Carolina | United States | 29621 |
425 | McLeod Regional Medical Center | Florence | South Carolina | United States | 29506 |
426 | Rapid City Regional Hospital | Rapid City | South Dakota | United States | 57701 |
427 | Sanford Cancer Center-Oncology Clinic | Sioux Falls | South Dakota | United States | 57104 |
428 | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota | United States | 57117-5134 |
429 | M D Anderson Cancer Center | Houston | Texas | United States | 77030 |
430 | Fredericksburg Oncology Inc | Fredericksburg | Virginia | United States | 22401 |
431 | Virginia Mason Medical Center | Seattle | Washington | United States | 98101 |
432 | Pacific Medical Center-First Hill | Seattle | Washington | United States | 98104 |
433 | Aurora Cancer Care-Southern Lakes VLCC | Burlington | Wisconsin | United States | 53105 |
434 | Marshfield Clinic-Chippewa Center | Chippewa Falls | Wisconsin | United States | 54729 |
435 | Marshfield Clinic Cancer Center at Sacred Heart | Eau Claire | Wisconsin | United States | 54701 |
436 | Sacred Heart Hospital | Eau Claire | Wisconsin | United States | 54701 |
437 | Aurora Health Center-Fond du Lac | Fond Du Lac | Wisconsin | United States | 54937 |
438 | Aurora Health Care Germantown Health Center | Germantown | Wisconsin | United States | 53022 |
439 | Aurora Cancer Care-Grafton | Grafton | Wisconsin | United States | 53024 |
440 | Green Bay Oncology at Saint Vincent Hospital | Green Bay | Wisconsin | United States | 54301-3526 |
441 | Saint Vincent Hospital Cancer Center Green Bay | Green Bay | Wisconsin | United States | 54301 |
442 | Green Bay Oncology Limited at Saint Mary's Hospital | Green Bay | Wisconsin | United States | 54303 |
443 | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay | Wisconsin | United States | 54303 |
444 | Aurora BayCare Medical Center | Green Bay | Wisconsin | United States | 54311 |
445 | Mercy Health System | Janesville | Wisconsin | United States | 53547 |
446 | Aurora Cancer Care-Kenosha South | Kenosha | Wisconsin | United States | 53142 |
447 | Holy Family Memorial Hospital | Manitowoc | Wisconsin | United States | 54221 |
448 | Bay Area Medical Center | Marinette | Wisconsin | United States | 54143 |
449 | Vince Lombardi Cancer Clinic-Marinette | Marinette | Wisconsin | United States | 54143 |
450 | Marshfield Clinic | Marshfield | Wisconsin | United States | 54449 |
451 | Saint Joseph's Hospital | Marshfield | Wisconsin | United States | 54449 |
452 | Aurora Cancer Care-Milwaukee | Milwaukee | Wisconsin | United States | 53209 |
453 | Aurora Saint Luke's Medical Center | Milwaukee | Wisconsin | United States | 53215 |
454 | Aurora Sinai Medical Center | Milwaukee | Wisconsin | United States | 53233 |
455 | Marshfield Clinic-Minocqua Center | Minocqua | Wisconsin | United States | 54548 |
456 | ProHealth D N Greenwald Center | Mukwonago | Wisconsin | United States | 53149 |
457 | Cancer Center of Western Wisconsin | New Richmond | Wisconsin | United States | 54017 |
458 | ProHealth Oconomowoc Memorial Hospital | Oconomowoc | Wisconsin | United States | 53066 |
459 | Green Bay Oncology - Oconto Falls | Oconto Falls | Wisconsin | United States | 54154 |
460 | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh | Wisconsin | United States | 54904 |
461 | Aurora Cancer Care-Racine | Racine | Wisconsin | United States | 53406 |
462 | Marshfield Clinic at James Beck Cancer Center | Rhinelander | Wisconsin | United States | 54501 |
463 | Saint Mary's Hospital | Rhinelander | Wisconsin | United States | 54501 |
464 | Lakeview Medical Center-Marshfield Clinic | Rice Lake | Wisconsin | United States | 54868 |
465 | Marshfield Clinic-Rice Lake Center | Rice Lake | Wisconsin | United States | 54868 |
466 | HSHS Saint Nicholas Hospital | Sheboygan | Wisconsin | United States | 53081 |
467 | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan | Wisconsin | United States | 53081 |
468 | Marshfield Clinic Cancer Care at Saint Michael's Hospital | Stevens Point | Wisconsin | United States | 54481 |
469 | Saint Michael's Hospital | Stevens Point | Wisconsin | United States | 54481 |
470 | Green Bay Oncology - Sturgeon Bay | Sturgeon Bay | Wisconsin | United States | 54235 |
471 | Aurora Medical Center in Summit | Summit | Wisconsin | United States | 53066 |
472 | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers | Wisconsin | United States | 54241 |
473 | Aurora Cancer Care-Waukesha | Waukesha | Wisconsin | United States | 53188 |
474 | ProHealth Waukesha Memorial Hospital | Waukesha | Wisconsin | United States | 53188 |
475 | UW Cancer Center at ProHealth Care | Waukesha | Wisconsin | United States | 53188 |
476 | Marshfield Clinic-Wausau Center | Wausau | Wisconsin | United States | 54401 |
477 | Aurora Cancer Care-Milwaukee West | Wauwatosa | Wisconsin | United States | 53226 |
478 | Aurora West Allis Medical Center | West Allis | Wisconsin | United States | 53227 |
479 | Marshfield Clinic - Weston Center | Weston | Wisconsin | United States | 54476 |
480 | Saint Clare's Hospital | Weston | Wisconsin | United States | 54476 |
481 | Marshfield Clinic - Wisconsin Rapids Center | Wisconsin Rapids | Wisconsin | United States | 54494 |
482 | Rocky Mountain Oncology | Casper | Wyoming | United States | 82609 |
483 | Big Horn Basin Cancer Center | Cody | Wyoming | United States | 82414 |
484 | Billings Clinic-Cody | Cody | Wyoming | United States | 82414 |
485 | Welch Cancer Center | Sheridan | Wyoming | United States | 82801 |
Sponsors and Collaborators
- Southwest Oncology Group
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Sikander Ailawadhi, Southwest Oncology Group
Study Documents (Full-Text)
More Information
Publications
None provided.- S1304
- NCI-2013-00796
- PS1304_A07PAMDREVW01
- SWOG-S1304
- S1304
- S1304
- U10CA180888
- U10CA032102
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Arm I (Dexamethasone, Low-dose Carfilzomib) | Arm II (Dexamethasone, High-dose Carfilzomib) |
---|---|---|
Arm/Group Description | Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies | Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies |
Period Title: Overall Study | ||
STARTED | 72 | 71 |
Crossover to Arm II | 16 | 0 |
COMPLETED | 64 | 57 |
NOT COMPLETED | 8 | 14 |
Baseline Characteristics
Arm/Group Title | Arm I (Dexamethasone, Low-dose Carfilzomib) | Arm II (Dexamethasone, High-dose Carfilzomib) | Total |
---|---|---|---|
Arm/Group Description | Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies | Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies | Total of all reporting groups |
Overall Participants | 64 | 57 | 121 |
Age, Customized (Count of Participants) | |||
Age >= 65 |
31
48.4%
|
32
56.1%
|
63
52.1%
|
Age < 65 |
33
51.6%
|
25
43.9%
|
58
47.9%
|
Sex: Female, Male (Count of Participants) | |||
Female |
31
48.4%
|
24
42.1%
|
55
45.5%
|
Male |
33
51.6%
|
33
57.9%
|
66
54.5%
|
Race (NIH/OMB) (Count of Participants) | |||
American Indian or Alaska Native |
1
1.6%
|
0
0%
|
1
0.8%
|
Asian |
1
1.6%
|
4
7%
|
5
4.1%
|
Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
Black or African American |
11
17.2%
|
8
14%
|
19
15.7%
|
White |
51
79.7%
|
41
71.9%
|
92
76%
|
More than one race |
0
0%
|
1
1.8%
|
1
0.8%
|
Unknown or Not Reported |
0
0%
|
3
5.3%
|
3
2.5%
|
Zubrod performance status > 1 (Count of Participants) | |||
Count of Participants [Participants] |
2
3.1%
|
3
5.3%
|
5
4.1%
|
Beta-2-microglobulin >=3.5 mg/L (Count of Participants) | |||
Count of Participants [Participants] |
36
56.3%
|
31
54.4%
|
67
55.4%
|
CRP >= 8 mg/L (Count of Participants) | |||
Count of Participants [Participants] |
6
9.4%
|
6
10.5%
|
12
9.9%
|
Creatinine >= 2 mg/dl (Count of Participants) | |||
Count of Participants [Participants] |
1
1.6%
|
0
0%
|
1
0.8%
|
Creatinine clearance < 60 ml/min (Count of Participants) | |||
Count of Participants [Participants] |
23
35.9%
|
18
31.6%
|
41
33.9%
|
LDH >= 190 U/L (Count of Participants) | |||
Count of Participants [Participants] |
31
48.4%
|
26
45.6%
|
57
47.1%
|
Albumin < 3.5 g/dl (Count of Participants) | |||
Count of Participants [Participants] |
16
25%
|
14
24.6%
|
30
24.8%
|
ISS disease stage: Stage 1 (Count of Participants) | |||
Count of Participants [Participants] |
20
31.3%
|
22
38.6%
|
42
34.7%
|
ISS disease stage: Stage 2 (Count of Participants) | |||
Count of Participants [Participants] |
30
46.9%
|
19
33.3%
|
49
40.5%
|
ISS disease stage: Stage 3 (Count of Participants) | |||
Count of Participants [Participants] |
14
21.9%
|
16
28.1%
|
30
24.8%
|
Hemoglobin <10 g/dL (Count of Participants) | |||
Count of Participants [Participants] |
15
23.4%
|
6
10.5%
|
21
17.4%
|
Platelet count < 150 x 10^9/L (Count of Participants) | |||
Count of Participants [Participants] |
1
1.6%
|
1
1.8%
|
2
1.7%
|
4-6 Prior lines of therapy (Count of Participants) | |||
Count of Participants [Participants] |
14
21.9%
|
15
26.3%
|
29
24%
|
Refractory to Bortezomib (Count of Participants) | |||
Count of Participants [Participants] |
32
50%
|
28
49.1%
|
60
49.6%
|
Serum M spike >3 g/dL (Count of Participants) | |||
Count of Participants [Participants] |
13
20.3%
|
6
10.5%
|
19
15.7%
|
Bone marrow plasma cells > 60% (Count of Participants) | |||
Count of Participants [Participants] |
14
21.9%
|
11
19.3%
|
25
20.7%
|
sLFC Ratio >=100 (Count of Participants) | |||
Count of Participants [Participants] |
24
37.5%
|
19
33.3%
|
43
35.5%
|
Myeloma isotype: IgG (Count of Participants) | |||
Count of Participants [Participants] |
36
56.3%
|
24
42.1%
|
60
49.6%
|
Myeloma isotype: IgA (Count of Participants) | |||
Count of Participants [Participants] |
5
7.8%
|
12
21.1%
|
17
14%
|
Myeloma isotype: light chain only (Count of Participants) | |||
Count of Participants [Participants] |
9
14.1%
|
8
14%
|
17
14%
|
Outcome Measures
Title | Progression-free Survival |
---|---|
Description | Assessed in each arm using the method of Kaplan Meier and compared between arms using the stratified long-rank test. Progression is defined using the International Uniform Response Criteria for Multiple Myeloma as new or increase in size of existing bone lesions or soft tissue plasmacytomas; or development of hypercalcemia attributable solely to MM; or ≥ 25% increase from baseline or lowest response level of either serum M protein, urine M protein, difference in involved & uninvolved serum free light chain level or bone marrow plasma cell percentage. |
Time Frame | From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 2 years |
Outcome Measure Data
Analysis Population Description |
---|
Group of participants that were eligible and analyzable per protocol. |
Arm/Group Title | Arm I (Dexamethasone, Low-dose Carfilzomib) | Arm II (Dexamethasone, High-dose Carfilzomib) |
---|---|---|
Arm/Group Description | Patients receive 20 mg dexamethasone IV and low-dose (27 mg/m^2) carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose of 20 mg/m^2.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies | Patients receive 20 mg dexamethasone IV and high-dose (56 mg/m^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose of 20 mg/m^2 over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies |
Measure Participants | 64 | 57 |
Median (95% Confidence Interval) [months] |
5
|
8
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Arm I (Dexamethasone, Low-dose Carfilzomib), Arm II (Dexamethasone, High-dose Carfilzomib) |
---|---|---|
Comments | ||
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.384 |
Comments | Stratified by pre-specified randomization stratification factors: 1 - 3 prior therapies vs. 4-6 prior therapies and refractory to bortezomib vs. not refractory to bortezomib. | |
Method | Log Rank | |
Comments | One-sided stratified log rank test | |
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 1.061 | |
Confidence Interval |
(2-Sided) 80% 0.821 to 1.370 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Title | Overall Survival |
---|---|
Description | Assessed in each arm using the method of Kaplan Meier and compared between arms using the stratified log-rank test. |
Time Frame | From date of registration to date of death due to any cause, assessed up to 3 years |
Outcome Measure Data
Analysis Population Description |
---|
Participants that were eligible and analyzable per protocol. |
Arm/Group Title | Arm I (Dexamethasone, Low-dose Carfilzomib) | Arm II (Dexamethasone, High-dose Carfilzomib) |
---|---|---|
Arm/Group Description | Patients receive 20 mg dexamethasone IV and low-dose (27 mg/m^2) carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose of 20 mg/m^2.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies | Patients receive 20 mg dexamethasone IV and high-dose (56 mg/m^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose of 20 mg/m^2 over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies |
Measure Participants | 64 | 57 |
Median (95% Confidence Interval) [months] |
26
|
22
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Arm I (Dexamethasone, Low-dose Carfilzomib), Arm II (Dexamethasone, High-dose Carfilzomib) |
---|---|---|
Comments | ||
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.284 |
Comments | Stratified by pre-specified randomization stratification factors: 1 - 3 prior therapies vs. 4-6 prior therapies and refractory to bortezomib vs. not refractory to bortezomib. | |
Method | Log Rank | |
Comments | One-sided stratified log rank test | |
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 1.149 | |
Confidence Interval |
(2-Sided) 80% 0.841 to 1.571 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Title | Best Overall Response - Partial Response (PR), Very Good Partial Response (VGPR), Unconfirmed PR (uPR), Stable Disease (SD) Progression (PROG) |
---|---|
Description | Per International Uniform Response Criteria for Multiple Myeloma PR- ≥ 50% reduction in size of soft tissue plasmacytomas & plasma cells; ≥ 50% decrease in serum & reduction in urine M protein ≥ 90% or to < 200 mg/24hr or ≥ 50% decrease in difference in uninvolved & involved serum free light chain levels; VGPR- PR + Serum and urine M proteins detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M protein & urine M protein < 100 mg/24 hrs; uPR- 1 objective status of PR, but confirmation studies are not done, or do not meet the requirements necessary to confirm response; SD- does not meet criteria for sCR, CR, VGPR, PR or PROG; PROG- new or increase in size of existing bone lesions or soft tissue plasmacytomas/ development of hypercalcemia attributable solely to MM/ ≥ 25% increase from baseline/ lowest response level of either serum or Urine M protein, difference in involved & uninvolved serum free light chain level or bone marrow plasma cell percentage. |
Time Frame | From date of registration to date of best response while on study treatment |
Outcome Measure Data
Analysis Population Description |
---|
This population includes eligible and analyzable patients who had a follow-up response assessment. |
Arm/Group Title | Arm I (Dexamethasone, Low-dose Carfilzomib) | Arm II (Dexamethasone, High-dose Carfilzomib) |
---|---|---|
Arm/Group Description | Patients receive 20 mg dexamethasone IV and low-dose (27 mg/m^2) carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose of 20 mg/m^2.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies | Patients receive 20 mg dexamethasone IV and high-dose (56 mg/m^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose of 20 mg/m^2 over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies |
Measure Participants | 59 | 53 |
Very Good Partial Response (VGPR) |
5
7.8%
|
14
24.6%
|
Partial Response (PR) |
18
28.1%
|
11
19.3%
|
Unconfirmed Partial Response (uPR) |
0
0%
|
2
3.5%
|
Stable Disease (SD) |
24
37.5%
|
19
33.3%
|
Progressive Disease |
12
18.8%
|
7
12.3%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Arm I (Dexamethasone, Low-dose Carfilzomib), Arm II (Dexamethasone, High-dose Carfilzomib) |
---|---|---|
Comments | Compare the rate of confirmed PR or better between treatment arms. | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1130 |
Comments | ||
Method | Cochran-Mantel-Haenszel | |
Comments |
Title | Progression-free Survival of Crossover Group |
---|---|
Description | Assessed in the crossover arm using the method of Kaplan Meier. Progression is defined using the International Uniform Response Criteria for Multiple Myeloma as new or increase in size of existing bone lesions or soft tissue plasmacytomas; or development of hypercalcemia attributable solely to MM; or ≥ 25% increase from baseline or lowest response level of either serum M protein, urine M protein, difference in involved & uninvolved serum free light chain level or bone marrow plasma cell percentage. |
Time Frame | From date of crossover to date of subsequent documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years from randomization |
Outcome Measure Data
Analysis Population Description |
---|
Patients on Arm 1 that progress after the start of course 2 and prior to completion of 12 courses receive high dose carfilzomib |
Arm/Group Title | Arm III (Crossover Group) |
---|---|
Arm/Group Description | Patients on Arm 1 that progress after the start of course 2 and prior to completion of 12 courses receive 20 mg dexamethasone IV and high-dose (56 mg/m^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 additional courses in the absence of disease progression or unacceptable toxicity. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies |
Measure Participants | 16 |
Median (95% Confidence Interval) [months] |
3
|
Title | Overall Survival Crossover Group |
---|---|
Description | Assessed in the crossover arm using the method of Kaplan Meier. |
Time Frame | From date of crossover to date of death due to any cause, assessed up to 3 years from randomization |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Crossover Arm |
---|---|
Arm/Group Description | Patients on Arm 1 that progress after the start of course 2 and prior to completion of 12 courses receive 20 mg dexamethasone IV and high-dose (56 mg/m^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 additional courses in the absence of disease progression or unacceptable toxicity. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies |
Measure Participants | 16 |
Median (95% Confidence Interval) [months] |
15
|
Title | Gene Expression Profiles |
---|---|
Description | Bone marrow compared to that of an aspirate taken at the site of the EMP. Data will be log-transformed before analysis. Exploratory analyses will examine underlying distributions using boxplots, density plots, scatter plots, etc. For differential expression analysis of the two sample types t-tests will be conducted on genes. False discovery rate will be used to control the average false positive proportions among selected genes. Genes will be ranked by their q-value and pathway analysis conducted upon selected genes to determine biological plausibility and relevance to molecular functionality. |
Time Frame | Up to 3 years |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title |
---|
Arm/Group Description |
Title | Incidence of CR by PET, Defined as the Disappearance of All Focal Lesions and the Resolution of EMD |
---|---|
Description | Univariate and multivariate logistic regression will be used to determine the impact of biochemical CR on CR by PET. In the multivariate analysis adjustment for standard prognostic factors such as age, albumin, beta-2 microglobulin, serum creatinine, c-reactive protein and lactate dehydrogenase will be included. |
Time Frame | Up to week 45 |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title |
---|
Arm/Group Description |
Adverse Events
Time Frame | For the duration of treatment, up to 12 cycles and maximum follow up of 3 years post-registration. | |||||
---|---|---|---|---|---|---|
Adverse Event Reporting Description | Note that denominators differ from those reported in other Results sections as the AE data tables are pulled from the live database and thus reflect more current data while other Sections are based those data reported at the time of Primary Endpoint analyses. | |||||
Arm/Group Title | Arm I (Dexamethasone, Low-dose Carfilzomib) | Arm II (Dexamethasone, High-dose Carfilzomib) | Crossover Arm | |||
Arm/Group Description | Patients receive dexamethasone and low dose carfilzomib. Includes all eligible and analyzable patients. Deaths for patients that registered Crossover arm are also counted in this arm. | Patients receive dexamethasone and high dose carfilzomib. Includes all eligible and analyzable patients. | Patients on Arm 1 that progress after the start of cycle 2 and prior to completion of 12 cycles receive high dose carfilzomib. Includes all eligible and analyzable patients. These patients are also included under "Arm I". | |||
All Cause Mortality |
||||||
Arm I (Dexamethasone, Low-dose Carfilzomib) | Arm II (Dexamethasone, High-dose Carfilzomib) | Crossover Arm | ||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 38/66 (57.6%) | 40/57 (70.2%) | 12/16 (75%) | |||
Serious Adverse Events |
||||||
Arm I (Dexamethasone, Low-dose Carfilzomib) | Arm II (Dexamethasone, High-dose Carfilzomib) | Crossover Arm | ||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 26/66 (39.4%) | 27/57 (47.4%) | 5/16 (31.3%) | |||
Blood and lymphatic system disorders | ||||||
Anemia | 3/66 (4.5%) | 6/57 (10.5%) | 1/16 (6.3%) | |||
Febrile neutropenia | 0/66 (0%) | 1/57 (1.8%) | 1/16 (6.3%) | |||
Cardiac disorders | ||||||
Acute coronary syndrome | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Atrial flutter | 0/66 (0%) | 0/57 (0%) | 1/16 (6.3%) | |||
Cardiac arrest | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Chest pain - cardiac | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Heart failure | 2/66 (3%) | 2/57 (3.5%) | 0/16 (0%) | |||
Left ventricular systolic dysfunction | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Restrictive cardiomyopathy | 2/66 (3%) | 0/57 (0%) | 0/16 (0%) | |||
Sinus tachycardia | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Supraventricular tachycardia | 0/66 (0%) | 0/57 (0%) | 1/16 (6.3%) | |||
Eye disorders | ||||||
Blurred vision | 2/66 (3%) | 0/57 (0%) | 0/16 (0%) | |||
Glaucoma | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Gastrointestinal disorders | ||||||
Gastroesophageal reflux disease | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Nausea | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Vomiting | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
General disorders | ||||||
Chills | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Death NOS | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
Edema limbs | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
Fatigue | 2/66 (3%) | 3/57 (5.3%) | 0/16 (0%) | |||
Fever | 2/66 (3%) | 6/57 (10.5%) | 0/16 (0%) | |||
Multi-organ failure | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Non-cardiac chest pain | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
Sudden death NOS | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Hepatobiliary disorders | ||||||
Cholecystitis | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Infections and infestations | ||||||
Endocarditis infective | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Infections and infestations-Other | 2/66 (3%) | 0/57 (0%) | 0/16 (0%) | |||
Lung infection | 3/66 (4.5%) | 7/57 (12.3%) | 1/16 (6.3%) | |||
Otitis media | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Sepsis | 2/66 (3%) | 3/57 (5.3%) | 2/16 (12.5%) | |||
Sinusitis | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Urinary tract infection | 1/66 (1.5%) | 2/57 (3.5%) | 0/16 (0%) | |||
Injury, poisoning and procedural complications | ||||||
Fall | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
Fracture | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
Injury, poison and procedural complications - Other | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Investigations | ||||||
Creatinine increased | 2/66 (3%) | 2/57 (3.5%) | 0/16 (0%) | |||
Ejection fraction decreased | 2/66 (3%) | 1/57 (1.8%) | 0/16 (0%) | |||
Lymphocyte count decreased | 2/66 (3%) | 3/57 (5.3%) | 0/16 (0%) | |||
Lymphocyte count increased | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Neutrophil count decreased | 1/66 (1.5%) | 0/57 (0%) | 1/16 (6.3%) | |||
Platelet count decreased | 4/66 (6.1%) | 7/57 (12.3%) | 1/16 (6.3%) | |||
White blood cell decreased | 1/66 (1.5%) | 0/57 (0%) | 1/16 (6.3%) | |||
Metabolism and nutrition disorders | ||||||
Anorexia | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Dehydration | 3/66 (4.5%) | 0/57 (0%) | 0/16 (0%) | |||
Hypercalcemia | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
Hyperglycemia | 0/66 (0%) | 2/57 (3.5%) | 0/16 (0%) | |||
Hypoalbuminemia | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Hypocalcemia | 0/66 (0%) | 2/57 (3.5%) | 0/16 (0%) | |||
Hypokalemia | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Hyponatremia | 1/66 (1.5%) | 3/57 (5.3%) | 0/16 (0%) | |||
Hypophosphatemia | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Tumor lysis syndrome | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Musculoskeletal and connective tissue disorders | ||||||
Arthralgia | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Back pain | 0/66 (0%) | 3/57 (5.3%) | 0/16 (0%) | |||
Bone pain | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
Chest wall pain | 2/66 (3%) | 0/57 (0%) | 0/16 (0%) | |||
Generalized muscle weakness | 2/66 (3%) | 1/57 (1.8%) | 0/16 (0%) | |||
Muscle weakness lower limb | 0/66 (0%) | 2/57 (3.5%) | 0/16 (0%) | |||
Myalgia | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Pain in extremity | 0/66 (0%) | 2/57 (3.5%) | 0/16 (0%) | |||
Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||
Neoplasms benign, malignant and unspecified - Other | 1/66 (1.5%) | 0/57 (0%) | 1/16 (6.3%) | |||
Nervous system disorders | ||||||
Dizziness | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Nervous system disorders-Other | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Somnolence | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Stroke | 0/66 (0%) | 2/57 (3.5%) | 1/16 (6.3%) | |||
Syncope | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Psychiatric disorders | ||||||
Confusion | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Renal and urinary disorders | ||||||
Acute kidney injury | 2/66 (3%) | 2/57 (3.5%) | 1/16 (6.3%) | |||
Chronic kidney disease | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Hematuria | 0/66 (0%) | 2/57 (3.5%) | 0/16 (0%) | |||
Renal and urinary disorders-Other | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
Renal calculi | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Urinary retention | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Respiratory, thoracic and mediastinal disorders | ||||||
Adult respiratory distress syndrome | 0/66 (0%) | 2/57 (3.5%) | 0/16 (0%) | |||
Bronchopulmonary hemorrhage | 0/66 (0%) | 0/57 (0%) | 1/16 (6.3%) | |||
Cough | 1/66 (1.5%) | 0/57 (0%) | 0/16 (0%) | |||
Dyspnea | 1/66 (1.5%) | 4/57 (7%) | 0/16 (0%) | |||
Epistaxis | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Hiccups | 0/66 (0%) | 1/57 (1.8%) | 0/16 (0%) | |||
Hypoxia | 1/66 (1.5%) | 3/57 (5.3%) | 1/16 (6.3%) | |||
Pulmonary edema | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
Respiratory failure | 2/66 (3%) | 1/57 (1.8%) | 0/16 (0%) | |||
Vascular disorders | ||||||
Hypertension | 1/66 (1.5%) | 1/57 (1.8%) | 0/16 (0%) | |||
Hypotension | 2/66 (3%) | 1/57 (1.8%) | 0/16 (0%) | |||
Other (Not Including Serious) Adverse Events |
||||||
Arm I (Dexamethasone, Low-dose Carfilzomib) | Arm II (Dexamethasone, High-dose Carfilzomib) | Crossover Arm | ||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 66/66 (100%) | 55/57 (96.5%) | 14/16 (87.5%) | |||
Blood and lymphatic system disorders | ||||||
Anemia | 39/66 (59.1%) | 38/57 (66.7%) | 8/16 (50%) | |||
Cardiac disorders | ||||||
Cardiac disorders-Other | 5/66 (7.6%) | 2/57 (3.5%) | 0/16 (0%) | |||
Chest pain - cardiac | 1/66 (1.5%) | 3/57 (5.3%) | 1/16 (6.3%) | |||
Sinus bradycardia | 4/66 (6.1%) | 0/57 (0%) | 0/16 (0%) | |||
Sinus tachycardia | 7/66 (10.6%) | 3/57 (5.3%) | 0/16 (0%) | |||
Ear and labyrinth disorders | ||||||
Hearing impaired | 1/66 (1.5%) | 3/57 (5.3%) | 0/16 (0%) | |||
Eye disorders | ||||||
Blurred vision | 9/66 (13.6%) | 11/57 (19.3%) | 0/16 (0%) | |||
Watering eyes | 1/66 (1.5%) | 0/57 (0%) | 1/16 (6.3%) | |||
Gastrointestinal disorders | ||||||
Abdominal pain | 6/66 (9.1%) | 8/57 (14%) | 1/16 (6.3%) | |||
Bloating | 0/66 (0%) | 4/57 (7%) | 0/16 (0%) | |||
Constipation | 12/66 (18.2%) | 14/57 (24.6%) | 2/16 (12.5%) | |||
Diarrhea | 20/66 (30.3%) | 20/57 (35.1%) | 2/16 (12.5%) | |||
Dry mouth | 6/66 (9.1%) | 7/57 (12.3%) | 0/16 (0%) | |||
Dyspepsia | 5/66 (7.6%) | 7/57 (12.3%) | 0/16 (0%) | |||
Gastroesophageal reflux disease | 5/66 (7.6%) | 1/57 (1.8%) | 0/16 (0%) | |||
Mucositis oral | 4/66 (6.1%) | 4/57 (7%) | 0/16 (0%) | |||
Nausea | 25/66 (37.9%) | 21/57 (36.8%) | 5/16 (31.3%) | |||
Stomach pain | 2/66 (3%) | 3/57 (5.3%) | 2/16 (12.5%) | |||
Vomiting | 13/66 (19.7%) | 9/57 (15.8%) | 0/16 (0%) | |||
General disorders | ||||||
Chills | 5/66 (7.6%) | 5/57 (8.8%) | 2/16 (12.5%) | |||
Edema face | 5/66 (7.6%) | 1/57 (1.8%) | 1/16 (6.3%) | |||
Edema limbs | 14/66 (21.2%) | 9/57 (15.8%) | 1/16 (6.3%) | |||
Fatigue | 39/66 (59.1%) | 33/57 (57.9%) | 6/16 (37.5%) | |||
Fever | 9/66 (13.6%) | 5/57 (8.8%) | 2/16 (12.5%) | |||
Flu like symptoms | 5/66 (7.6%) | 2/57 (3.5%) | 1/16 (6.3%) | |||
Non-cardiac chest pain | 4/66 (6.1%) | 4/57 (7%) | 0/16 (0%) | |||
Pain | 13/66 (19.7%) | 15/57 (26.3%) | 1/16 (6.3%) | |||
Immune system disorders | ||||||
Allergic reaction | 0/66 (0%) | 0/57 (0%) | 1/16 (6.3%) | |||
Immune system disorders-Other | 1/66 (1.5%) | 1/57 (1.8%) | 1/16 (6.3%) | |||
Infections and infestations | ||||||
Infections and infestations-Other | 5/66 (7.6%) | 6/57 (10.5%) | 0/16 (0%) | |||
Sinusitis | 5/66 (7.6%) | 1/57 (1.8%) | 0/16 (0%) | |||
Skin infection | 1/66 (1.5%) | 0/57 (0%) | 1/16 (6.3%) | |||
Upper respiratory infection | 5/66 (7.6%) | 7/57 (12.3%) | 1/16 (6.3%) | |||
Injury, poisoning and procedural complications | ||||||
Bruising | 5/66 (7.6%) | 6/57 (10.5%) | 0/16 (0%) | |||
Fracture | 1/66 (1.5%) | 2/57 (3.5%) | 1/16 (6.3%) | |||
Investigations | ||||||
Alanine aminotransferase increased | 1/66 (1.5%) | 4/57 (7%) | 0/16 (0%) | |||
Alkaline phosphatase increased | 7/66 (10.6%) | 3/57 (5.3%) | 1/16 (6.3%) | |||
Aspartate aminotransferase increased | 7/66 (10.6%) | 8/57 (14%) | 0/16 (0%) | |||
Blood bilirubin increased | 8/66 (12.1%) | 4/57 (7%) | 0/16 (0%) | |||
Creatinine increased | 15/66 (22.7%) | 14/57 (24.6%) | 2/16 (12.5%) | |||
Lymphocyte count decreased | 18/66 (27.3%) | 16/57 (28.1%) | 4/16 (25%) | |||
Neutrophil count decreased | 13/66 (19.7%) | 14/57 (24.6%) | 1/16 (6.3%) | |||
Platelet count decreased | 28/66 (42.4%) | 29/57 (50.9%) | 5/16 (31.3%) | |||
Weight gain | 7/66 (10.6%) | 3/57 (5.3%) | 1/16 (6.3%) | |||
Weight loss | 5/66 (7.6%) | 8/57 (14%) | 0/16 (0%) | |||
White blood cell decreased | 21/66 (31.8%) | 24/57 (42.1%) | 3/16 (18.8%) | |||
Metabolism and nutrition disorders | ||||||
Anorexia | 12/66 (18.2%) | 13/57 (22.8%) | 0/16 (0%) | |||
Dehydration | 3/66 (4.5%) | 6/57 (10.5%) | 1/16 (6.3%) | |||
Hypercalcemia | 4/66 (6.1%) | 2/57 (3.5%) | 1/16 (6.3%) | |||
Hyperglycemia | 17/66 (25.8%) | 15/57 (26.3%) | 1/16 (6.3%) | |||
Hyperkalemia | 5/66 (7.6%) | 2/57 (3.5%) | 1/16 (6.3%) | |||
Hyperuricemia | 5/66 (7.6%) | 4/57 (7%) | 1/16 (6.3%) | |||
Hypoalbuminemia | 15/66 (22.7%) | 15/57 (26.3%) | 1/16 (6.3%) | |||
Hypocalcemia | 6/66 (9.1%) | 11/57 (19.3%) | 0/16 (0%) | |||
Hypokalemia | 13/66 (19.7%) | 3/57 (5.3%) | 2/16 (12.5%) | |||
Hypomagnesemia | 9/66 (13.6%) | 8/57 (14%) | 0/16 (0%) | |||
Hyponatremia | 9/66 (13.6%) | 11/57 (19.3%) | 1/16 (6.3%) | |||
Hypophosphatemia | 5/66 (7.6%) | 7/57 (12.3%) | 1/16 (6.3%) | |||
Metabolism and nutrition disorders - Other, specify | 2/66 (3%) | 3/57 (5.3%) | 1/16 (6.3%) | |||
Musculoskeletal and connective tissue disorders | ||||||
Arthralgia | 7/66 (10.6%) | 11/57 (19.3%) | 3/16 (18.8%) | |||
Back pain | 24/66 (36.4%) | 21/57 (36.8%) | 4/16 (25%) | |||
Bone pain | 8/66 (12.1%) | 6/57 (10.5%) | 0/16 (0%) | |||
Chest wall pain | 2/66 (3%) | 3/57 (5.3%) | 0/16 (0%) | |||
Generalized muscle weakness | 7/66 (10.6%) | 8/57 (14%) | 1/16 (6.3%) | |||
Musculoskeletal and connective tiss disorder - Other | 2/66 (3%) | 2/57 (3.5%) | 1/16 (6.3%) | |||
Myalgia | 8/66 (12.1%) | 5/57 (8.8%) | 1/16 (6.3%) | |||
Neck pain | 4/66 (6.1%) | 2/57 (3.5%) | 0/16 (0%) | |||
Pain in extremity | 16/66 (24.2%) | 15/57 (26.3%) | 3/16 (18.8%) | |||
Nervous system disorders | ||||||
Dizziness | 13/66 (19.7%) | 12/57 (21.1%) | 1/16 (6.3%) | |||
Dysgeusia | 3/66 (4.5%) | 4/57 (7%) | 1/16 (6.3%) | |||
Headache | 20/66 (30.3%) | 18/57 (31.6%) | 2/16 (12.5%) | |||
Nervous system disorders-Other | 1/66 (1.5%) | 3/57 (5.3%) | 0/16 (0%) | |||
Paresthesia | 5/66 (7.6%) | 4/57 (7%) | 0/16 (0%) | |||
Peripheral motor neuropathy | 0/66 (0%) | 5/57 (8.8%) | 0/16 (0%) | |||
Peripheral sensory neuropathy | 20/66 (30.3%) | 18/57 (31.6%) | 4/16 (25%) | |||
Psychiatric disorders | ||||||
Anxiety | 10/66 (15.2%) | 9/57 (15.8%) | 2/16 (12.5%) | |||
Confusion | 4/66 (6.1%) | 3/57 (5.3%) | 2/16 (12.5%) | |||
Depression | 8/66 (12.1%) | 3/57 (5.3%) | 2/16 (12.5%) | |||
Insomnia | 19/66 (28.8%) | 20/57 (35.1%) | 3/16 (18.8%) | |||
Renal and urinary disorders | ||||||
Acute kidney injury | 3/66 (4.5%) | 2/57 (3.5%) | 1/16 (6.3%) | |||
Chronic kidney disease | 2/66 (3%) | 3/57 (5.3%) | 1/16 (6.3%) | |||
Proteinuria | 6/66 (9.1%) | 2/57 (3.5%) | 0/16 (0%) | |||
Renal and urinary disorders-Other | 3/66 (4.5%) | 1/57 (1.8%) | 1/16 (6.3%) | |||
Urinary frequency | 2/66 (3%) | 4/57 (7%) | 0/16 (0%) | |||
Respiratory, thoracic and mediastinal disorders | ||||||
Cough | 22/66 (33.3%) | 17/57 (29.8%) | 2/16 (12.5%) | |||
Dyspnea | 22/66 (33.3%) | 27/57 (47.4%) | 3/16 (18.8%) | |||
Epistaxis | 1/66 (1.5%) | 3/57 (5.3%) | 0/16 (0%) | |||
Nasal congestion | 2/66 (3%) | 3/57 (5.3%) | 0/16 (0%) | |||
Productive cough | 4/66 (6.1%) | 3/57 (5.3%) | 0/16 (0%) | |||
Sinus disorder | 0/66 (0%) | 0/57 (0%) | 1/16 (6.3%) | |||
Sore throat | 2/66 (3%) | 4/57 (7%) | 1/16 (6.3%) | |||
Skin and subcutaneous tissue disorders | ||||||
Dry skin | 2/66 (3%) | 3/57 (5.3%) | 0/16 (0%) | |||
Pruritus | 5/66 (7.6%) | 5/57 (8.8%) | 0/16 (0%) | |||
Rash maculo-papular | 8/66 (12.1%) | 7/57 (12.3%) | 1/16 (6.3%) | |||
Skin and subcutaneous tissue disorders - Other | 4/66 (6.1%) | 1/57 (1.8%) | 0/16 (0%) | |||
Vascular disorders | ||||||
Flushing | 8/66 (12.1%) | 4/57 (7%) | 0/16 (0%) | |||
Hot flashes | 1/66 (1.5%) | 3/57 (5.3%) | 0/16 (0%) | |||
Hypertension | 16/66 (24.2%) | 20/57 (35.1%) | 2/16 (12.5%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
Name/Title | S1304 Statistician |
---|---|
Organization | SWOG Statistical Center |
Phone | 2066674623 |
rachaels@crab.org |
- S1304
- NCI-2013-00796
- PS1304_A07PAMDREVW01
- SWOG-S1304
- S1304
- S1304
- U10CA180888
- U10CA032102